UNSPSC 51121927: Monoxerutin

This classification denotes a flavonoid with the molecular formula C29H34O17, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EKF7043SBU, chemically known as 3,3,4,5-tetrahydroxy-7-(2-hydroxyethoxy)flavone 3-(6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside) but more generally known as monoxerutin, which bears U.S. NIH Compound Identifier 5464100. European Medicines Agency schedules Monoxerutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09053MIG.

UNSPSC 51121927 Monoxerutin is a Commodity code that captures emergency medical and pharmaceutical supplies procured by state and local health systems, fire departments, and pharmacy benefit programs. State and local governments buy specific pharmaceutical line items under this code — typically branded or generic injectable medications required for advanced life support protocols, emergency response, and managed pharmacy programs. The issuing bodies span municipal fire departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Work includes sealed competitive bidding for emergency medications, exploratory RFIs to establish direct-to-manufacturer prescription programs, and cooperative RFPs to establish framework agreements for generic pharmaceuticals and OTC products across multiple state and local member jurisdictions.

Recent activity clusters in Texas, Florida, and Minnesota. The City of Tampa Purchasing Department issued Bid No. 26-P-00188 on April 24, 2026, soliciting advanced life support medications (Labetalol HCI, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, with a 5 percent SLBE bid discount and a one-year term plus two optional one-year renewals. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities, seeking vendor experience with self-insured health plans and negotiated net-pricing models. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026 with a March 26, 2026 response deadline to establish multi-award framework contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, effective July 1, 2026, with contract terms of two years for new vendors and extended terms through June 30, 2028 for incumbents.